# Paysign Q3 2026 Earnings Report Highlights Growth

> Paysign's patient affordability programs drove 42.6% revenue growth and 204.1% net income increase in Q3 2026.
- Title: Paysign Q3 2026 Earnings Report Highlights Growth | Shortify
- Summary: Paysign's patient affordability programs drove 42.6% revenue growth and 204.1% net income increase in Q3 2026.
- Keywords: paysign, q3 2026, patient affordability, pharma revenue, plasma revenue, gross margin, net income, dynamic business rules, apherion, plasma centers, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/10/paysign-pays-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-10T06:27:00+00:00
- Read time: 1 min
- Topics: paysign, q3 2026, patient affordability, pharma revenue, plasma revenue, gross margin, net income, dynamic business rules, apherion, plasma centers, finance, money
## Q3 2026 Revenue
Revenue grew 42.6% year over year to $30.8 million.
## Pharma Revenue Growth
Pharma revenue increased 109.8% year over year to $16.6 million.
## Plasma Revenue
Plasma revenue grew 7.5% year over year to $13.8 million.
## Gross Margin Expansion
Gross margin expanded 840 basis points to 64.7% year over year.
## Net Income Growth
Net income grew 204.1% year over year to $6.7 million.
## Patient Affordability Programs
167 active patient affordability programs with 19 new launches in Q3.
## Average Program Revenue
Average quarterly revenue per pharma program increased to $99,524.
## Patient Financial Assistance
Delivered $367 million in patient financial assistance in Q3.
## Dynamic Business Rules Savings
Saved $82.5 million in client costs through dynamic business rules.
## Plasma Center Count
562 plasma centers at quarter-end, down from 595 centers last year.
## Average Plasma Revenue
Average monthly revenue per plasma center increased to $8,187.
## Operating Margin
Operating margin expanded to 23.8% from 7.3% last year.
## Plasma Transition Impact
113 plasma centers expected to transition to another provider in Q4.
## 2026 Revenue Guidance
Revenue guidance of $114 million to $117 million for 2026.
## 2026 Net Income Guidance
Net income guidance of $23 million to $24 million for 2026.
## 2026 Adjusted EBITDA Guidance
Adjusted EBITDA guidance of $38.5 million to $40.0 million for 2026.
## Key takeaway

Paysign reported $30.8 million revenue, 204.1% year-over-year net income growth, and 64.7% gross margins driven by patient affordability programs.